Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1977 1
1988 1
1997 1
2002 1
2004 3
2005 2
2006 2
2007 5
2008 3
2009 6
2010 4
2011 3
2012 3
2013 5
2014 7
2015 11
2016 23
2017 12
2018 15
2019 20
2020 23
2021 18
2022 19
2023 14
2024 21
2025 17
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Results by year

Filters applied: . Clear all
Page 1
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.
Kutsch N, Ligtvoet R, Robrecht S, Linde H, Illmer T, Dörfel S, Lipke J, Aldaoud A, Schlag R, Dengler J, Al-Sawaf O, Langerbeins P, Cramer P, Hallek M, Eichhorst B, Fischer K, Fink A. Kutsch N, et al. Among authors: eichhorst b. Eur J Haematol. 2026 Apr 14. doi: 10.1111/ejh.70178. Online ahead of print. Eur J Haematol. 2026. PMID: 41978941
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.
Fürstenau M, Niemann CU, Robrecht S, Rotbain EC, Eurelings LEM, Giza A, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindstrom V, Juliusson G, Janssens A, da Cunha-Bang C, Schneider C, Herishanu Y, O'Shea D, Baumann M, Widmer AA, Nösslinger T, Bjørn Poulsen C, Frederiksen H, Lotfi K, Ranti J, Enggaard L, Velders GA, Vekemans MM, de Heer K, Snijders TJF, Siemes C, Wendtner CM, Knauf WU, Kroeber A, Zahn MO, Illmer T, Schöttker B, Simon F, Fink AM, Fischer K, D'Brot R, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Levin MD, Hallek MJ, Kater AP, Eichhorst BF. Fürstenau M, et al. Among authors: eichhorst bf. Blood. 2026 Mar 30:blood.2025032160. doi: 10.1182/blood.2025032160. Online ahead of print. Blood. 2026. PMID: 41911073
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.
Simon F, Ligtvoet R, Fürstenau M, Langerbeins P, Fink AM, von Tresckow J, Cramer P, Kutsch N, Goede V, Poulsen CB, Illmer T, Müller L, Vehling-Kaiser U, Eckart M, Staber P, Tadmor T, Gregor M, Juliusson G, Thornton P, Sivcheva L, Loscertales J, Jentsch-Ullrich K, Hebart H, Levin MD, da Cunha-Bang C, Tausch E, Schneider C, Stilgenbauer S, Kater AP, Niemann CU, Fischer K, Robrecht S, Hallek M, Eichhorst B, Al-Sawaf O. Simon F, et al. Among authors: eichhorst b. Leuk Lymphoma. 2026 Mar 17:1-7. doi: 10.1080/10428194.2026.2634939. Online ahead of print. Leuk Lymphoma. 2026. PMID: 41841194 No abstract available.
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.
Al-Sawaf O, Locher BN, Christen F, Hablesreiter R, Rajamani A, Robrecht S, Zhang C, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Kopp K, Mertz ME, Fustero-Torre C, Kleo K, Seymour J, Blombery P, Bullinger L, Chyla B, Jin HY, Jiang Y, Stilgenbauer S, Hallek M, Eichhorst B, Langerbeins P, Fischer K, Damm F. Al-Sawaf O, et al. Among authors: eichhorst b. Blood. 2026 Mar 19;147(12):1323-1337. doi: 10.1182/blood.2025029905. Blood. 2026. PMID: 41528026 Free PMC article.
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial.
Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Mørch M, Oki T, Valentin R, Bellido M, Eichhorst B. Kater AP, et al. Among authors: eichhorst b. Lancet Haematol. 2026 Jan;13(1):e8-e21. doi: 10.1016/S2352-3026(25)00327-8. Epub 2025 Dec 8. Lancet Haematol. 2026. PMID: 41380698 Clinical Trial.
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfò L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M; CLL17 Trial Investigators. Al-Sawaf O, et al. Among authors: eichhorst b. N Engl J Med. 2026 Mar 12;394(11):1084-1096. doi: 10.1056/NEJMoa2515458. Epub 2025 Dec 6. N Engl J Med. 2026. PMID: 41358601 Clinical Trial.
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.
Visentin A, Gaffo E, Fürstenau M, Rogers KA, Panagiotis B, Cui C, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen-Khac F, Roncaglia E, Rigolin GM, Athanasiadou A, Baran-Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, Scarfò L, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Calabretto G, Ruocco V, Orsi S, Cellini A, Angotzi F, Serafin A, Yi S, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Bortoluzzi S. Visentin A, et al. Among authors: eichhorst b. Leukemia. 2025 Dec;39(12):2957-2967. doi: 10.1038/s41375-025-02755-8. Epub 2025 Sep 19. Leukemia. 2025. PMID: 40973766 Free PMC article.
Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.
Simon F, Ligtvoet R, Bohn JP, Nösslinger T, von Tresckow J, Liersch R, Gaska T, Jentsch-Ullrich K, Gärtner M, Wolff T, Schwaner I, Wolf D, Schneider C, Vehling-Kaiser U, Ritgen M, Spoer C, Eckart M, Decker T, Chakupurakal G, Schöttker B, Kisro J, Kreuzer KA, Tausch E, Stilgenbauer S, Robrecht S, Stumpf J, Fink AM, Fürstenau M, Fischer K, Goede V, Hallek M, Eichhorst B. Simon F, et al. Among authors: eichhorst b. Blood. 2025 Dec 25;146(26):3153-3162. doi: 10.1182/blood.2025028550. Blood. 2025. PMID: 40906922 Free PMC article. Clinical Trial.
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Al-Sawaf O, Fürstenau M, Giza A, Robrecht S, von Tresckow J, Fink AM, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindström V, Staber P, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann C, Fischer K, Eichhorst B, Hallek M. Al-Sawaf O, et al. Among authors: eichhorst b. Blood. 2025 Nov 13;146(20):2406-2416. doi: 10.1182/blood.2025028899. Blood. 2025. PMID: 40864973 Free PMC article.
210 results